Promising novel immunotherapies and combinations for prostate cancer

被引：25

作者：

Arlen, Philip M. ^{[1
]}

Mohebtash, Mahsa ^{[1
]}

Madan, Ravi A. ^{[1
]}

Gulley, James L. ^{[1
]}

机构：

[1] NCI, Tumor Immunol & Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA

来源：

FUTURE ONCOLOGY | 2009年 / 5卷 / 02期

关键词：

clinical trials; dendritic cells; immunology; poxviral vector; prostate cancer; vaccines; COLONY-STIMULATING FACTOR; REGULATORY T-CELLS; ANDROGEN-DEPRIVATION THERAPY; PHASE-I; COSTIMULATORY MOLECULES; IMMUNE-RESPONSES; CELLULAR IMMUNOTHERAPY; IMMUNOLOGICAL RESPONSE; RADIATION-THERAPY; CTLA-4; BLOCKADE;

D O I：

10.2217/14796694.5.2.187

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The field of therapeutic cancer vaccines is currently in a state of active preclinical and clinical investigation, and certain novel therapies involving tumor immunotherapy have recently come to the forefront of prostate cancer research, While no therapeutic cancer vaccine has yet been approved by the US FDA, recent findings have demonstrated that new paradigms of combination therapies involving vaccines, employed in clinical trials with appropriate design and end points, may ultimately lead to cancer vaccines being used to treat various malignancies. Several characteristics of prostate cancer make it an ideal target for immunotherapy. Its relative indolence allows sufficient time to generate immune responses, which usually take weeks or months to mount. In addition, prostate cancer-associated antigens direct the immune response to prostate cancer cells, thus sparing normal tissue. This review focuses on the future of promising new vaccines and novel perspectives in the treatment of prostate cancer.

引用

页码：187 / 196

页数：10

共 66 条

[1]

[Anonymous], 1988, Human Monkeypox

[2]

[Anonymous], 2008, J CLIN ONCOL, DOI DOI 10.1200/JCO.2008.26.15_SUPPL.5146

[3] Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer [J].

Aragon-Ching, Jeanny B. ;

Williams, Kirsten M. ;

Gulley, James L. .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :4957-4971

[4] Preclinical and clinical studies of recombinant poxvirus Vaccines for carcinoma therapy [J].

Arlen, Philip M. ;

Gulley, James L. ;

Madan, Ravi A. ;

Hodge, James W. ;

Schlom, Jeffrey .

CRITICAL REVIEWS IN IMMUNOLOGY, 2007, 27 (05) :451-462

[5] A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer [J].

Arlen, PM ;

Gulley, JL ;

Parker, C ;

Skarupa, L ;

Pazdur, M ;

Panicali, D ;

Beetham, P ;

Tsang, KY ;

Grosenbach, DW ;

Feldman, J ;

Steinberg, SM ;

Jones, E ;

Chen, C ;

Marte, J ;

Schlom, J ;

Dahut, W .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1260-1269

[6] Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer [J].

Arlen, PM ;

Gulley, JL ;

Todd, N ;

Lieberman, R ;

Steinberg, SM ;

Morin, S ;

Bastian, A ;

Marte, J ;

Tsang, KY ;

Beetham, P ;

Grosenbach, DW ;

Schlom, J ;

Dahut, W .

JOURNAL OF UROLOGY, 2005, 174 (02) :539-546

[7] Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma:: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes [J].

Audia, S. ;

Nicolas, A. ;

Cathelin, D. ;

Larmonier, N. ;

Ferrand, C. ;

Foucher, P. ;

Fanton, A. ;

Bergoin, E. ;

Maynadie, M. ;

Arnould, L. ;

Bateman, A. ;

Lorcerie, B. ;

Solary, E. ;

Chauffert, B. ;

Bonnotte, B. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 150 (03) :523-530

[8]

Beer TM, 2007, J CLIN ONCOL, V25

[9] Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer:: A phase 2 trial [J].

Burch, PA ;

Croghan, GA ;

Gastineau, DA ;

Jones, LA ;

Kaur, JS ;

Kylstra, JW ;

Richardson, RL ;

Valone, FH ;

Vuk-Pavlovic, S .

PROSTATE, 2004, 60 (03) :197-204

[10] Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy [J].

Chakraborty, M ;

Abrams, SI ;

Camphausen, K ;

Liu, KB ;

Scott, T ;

Coleman, CN ;

Hodge, JW .

JOURNAL OF IMMUNOLOGY, 2003, 170 (12) :6338-6347

← 1 2 3 4 5 6 7 →